OpenAI
October 20, 2026
Company
OpenAI acquires Orchestra Bio
AI-powered drug development platform accelerates progress toward new treatments.
Loading…
OpenAI has acquired Orchestra Bio(opens in a new window), a platform that helps biopharma teams coordinate the complex process of drug development. We’re bringing Orchestra’s team and technology together with Rosalind, our AI models and tools for life sciences research. Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.
Developing a new medicine is extraordinarily complex, taking roughly 10 to 15 years on average from target discovery to regulatory approval in the United States. Beyond the science, teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. We’re now at an inflection point where AI can help take on these specialized tasks and complex workflows.
Rosalind brings our AI models and tools to life sciences researchers. GPT‑Rosalind helps scientists reason through questions in biology and chemistry. Rosalind Workbench connects those capabilities with scientific tools and data to help researchers analyze results and plan experiments.
Orchestra brings a team with experience across biotech, software, and AI, along with a platform built to coordinate drug development. Together, we aim to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine.
Orchestra Bio is a platform where people and AI agents work together to advance drug programs. Scientists and program leaders delegate the monitoring and tracking of studies and campaigns to agents, freeing up time to guide the work, make decisions, and address issues before they cause delays.
A problem in one part of a drug program can affect many others. A failed manufacturing batch, for example, can delay the start of a clinical trial. Orchestra’s agents help teams identify which activities and timelines are affected, gather the relevant information, and compare ways to respond. Scientists and program leaders can then use that analysis to decide what to do next.
Realizing the potential of AI in life sciences requires close collaboration with the organizations working at the forefront of drug discovery and development. Our partnership with Novo Nordisk aims to translate its scale and scientific expertise into faster R&D and commercial execution while maintaining strong governance. At Moderna, AI is helping teams translate insights from complex data into experimental workflows, with the potential to accelerate R&D.
Our vision is for AI to help scientists across the full process of discovering and developing new medicines: exploring ideas, designing experiments, interpreting results, and coordinating the work needed to advance promising treatments. Bringing Orchestra Bio together with Rosalind is a step toward that vision. Alongside researchers and our partners, we aim to make more discoveries possible and help new medicines reach patients sooner.
2026
Keep reading
View all
Introducing the Rosalind Academic Plan
ResearchOct 15, 2026
How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules
Applied AISep 10, 2026
Introducing new capabilities to GPT-Rosalind
ProductJun 3, 2026